United States - English - NLM (National Library of Medicine)

amgen inc - erenumab (unii: i5i8vb78vt) (erenumab - unii:i5i8vb78vt) - aimovig is indicated for the preventive treatment of migraine in adults. aimovig is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients. reactions have included anaphylaxis and angioedema [see warnings and precautions (5.1)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to aimovig during pregnancy. patients should be encouraged to enroll by calling 1-833-244-4083 or visiting https://www.genesispregnancyregistry.com/. risk summary there are no adequate data on the developmental risk associated with the use of aimovig in pregnant women. no adverse effects on offspring were observed when pregnant monkeys were administered erenumab-aooe throughout gestation [see data]. serum erenumab-aooe exposures in pregnant monkeys were greater than those in humans at clinical doses. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recogni

Israel - English - Ministry of Health

novartis israel ltd - erenumab - solution for injection - erenumab 140 mg / 1 ml - erenumab - aimovig is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month when initiating treatment with aimovig

Israel - English - Ministry of Health

novartis israel ltd - erenumab - solution for injection - erenumab 70 mg / 1 ml - erenumab - aimovig is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month when initiating treatment with aimovig

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - erenumab, quantity: 70 mg - injection, solution - excipient ingredients: glacial acetic acid; sodium hydroxide; polysorbate 80; water for injections; sucrose - aimovig is indicated for prophylaxis of migraine in adults

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - erenumab, quantity: 70 mg - injection, solution - excipient ingredients: water for injections; sucrose; polysorbate 80; sodium hydroxide; glacial acetic acid - aimovig is indicated for prophylaxis of migraine in adults

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - erenumab, quantity: 140 mg - injection, solution - excipient ingredients: sucrose; polysorbate 80; glacial acetic acid; sodium hydroxide; water for injections - aimovig is indicated for prophylaxis of migraine in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - erenumab, quantity: 140 mg - injection, solution - excipient ingredients: sucrose; polysorbate 80; glacial acetic acid; sodium hydroxide; water for injections - aimovig is indicated for prophylaxis of migraine in adults.

European Union - English - EMA (European Medicines Agency)

novartis europharm limited - erenumab - migraine disorders - analgesics - aimovig is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month when initiating treatment with aimovig.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - erenumab -

Canada - English - Health Canada

novartis pharmaceuticals canada inc - erenumab - solution - 70mg - erenumab 70mg - calcitonin-gene-related peptide (cgrp) antagonists